Nexlizet 180 mg/1
Bempedoic Acid and Ezetimibe · TABLET, FILM COATED · Esperion Therapeutics, Inc.
Nexlizet is a tablet, film coated containing bempedoic acid and ezetimibe at 180 mg/1, taken oral. Manufactured by Esperion Therapeutics, Inc..
Key Facts
- Brand Name
- Nexlizet
- Generic Name
- Bempedoic Acid and Ezetimibe
- NDC Code (Product)
72426-818- Manufacturer
- Esperion Therapeutics, Inc.
- Strength
- 180 mg/1
- Dosage Form
- TABLET, FILM COATED
- Route
- ORAL
- Marketing Status
- Application #
- NDA211617
- Drug Class
- Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC]; Dietary Cholesterol Absorption Inhibitor [EPC]
- Marketing Start
- 03/09/2020
Recall History
No Recall HistoryFrequently Asked Questions
What is Nexlizet used for?
Nexlizet contains Bempedoic Acid and Ezetimibe. It is a tablet, film coated taken oral. Consult your doctor for specific uses.
Is Nexlizet a controlled substance?
Nexlizet is not classified as a controlled substance by the DEA.
What is the generic name for Nexlizet?
The generic name for Nexlizet is Bempedoic Acid and Ezetimibe. There are no other listed brand versions of Bempedoic Acid and Ezetimibe.
What is the NDC code for Nexlizet 180 mg/1?
The NDC (National Drug Code) for Nexlizet 180 mg/1 is 72426-818, listed by Esperion Therapeutics, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)